Coherus Oncology, Inc.
CHRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001512762
No open-market purchases or sales by Coherus Oncology, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Coherus Oncology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Coherus Oncology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Wahlstrom Mats | Director | 30,000 | Jun 9, 2026 | 1 |
| Karachun Rita A | Director | 30,000 | Jun 9, 2026 | 1 |
| Satvat Ali J. | Director | 30,000 | Jun 9, 2026 | 1 |
| Newcomer Lee Nisley | Director | 30,000 | Jun 9, 2026 | 1 |
| Newton Charles W. | Director | 30,000 | Jun 9, 2026 | 1 |
| O'Donnell-Tormey Jill | Director | 30,000 | Jun 9, 2026 | 1 |
| Ryan Michael Lee | Director | 30,000 | Jun 9, 2026 | 1 |
| Lanfear Dennis M | President & CEO | 1,048,235 | Jun 2, 2026 | 3 |
| McMichael Bryan J | Chief Financial Officer | 133,736 | Jun 2, 2026 | 3 |
| Erbez Georgia | Director | – | Jun 13, 2025 | 0 |
| Reider Paul | Chief Commercial Officer | 82,069 | Jan 22, 2025 | 0 |
| Stolper Mark | Director | – | Jun 5, 2024 | 0 |
| Tzoumakas Kimberly Jo | Director | – | Jun 5, 2024 | 0 |
| Stilwell McDavid | Chief Financial Officer | 75,305 | Jan 3, 2024 | 0 |
| Vexler Vladimir | Chief Scientific Officer | 116,361 | Apr 4, 2023 | 0 |
| Healy James | Director | 0Indirect | Feb 11, 2022 | 0 |
| Anicetti Vincent R | Chief Operating Officer | 124,790 | Jul 8, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 28, 2025 (view filing) | May 23 | 5 days | Wahlstrom MatsDirector | SSale | −100.0K | $0.74 | −$74.0K | −100.0%0 after | |
| Nov 24, 2023 (view filing) | Nov 22 | 2 days | Lanfear Dennis MPresident & CEO | SSale | −223.1K | $2.02 | −$450.7K | −23.4%731.7K after | |
| Oct 19, 2021 (view filing) | Oct 15 | 4 days | Stilwell McDavidChief Financial Officer | SSale | −3.51K | $16.80 | −$58.9K | −10.0%31.6K after | |
| Sep 29, 2021 (view filing) | Sep 27-29 | 2 days | Healy JamesDirector | SSaleCommon Stock, $0.0001 par value | −434.6K | $16.68 | −$7.25M | −100.0%0 after | 3 lots |